286 related articles for article (PubMed ID: 35196819)
1. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
3. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ
PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095
[TBL] [Abstract][Full Text] [Related]
4. A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021.
Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Robbins NF; Orjuela G; Jenkins C; Conrod V; Yi QL; O'Brien SF; Drews SJ
Microbiol Spectr; 2022 Jun; 10(3):e0113422. PubMed ID: 35652636
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
6. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
[TBL] [Abstract][Full Text] [Related]
7. Saliva SARS-CoV-2 Antibody Prevalence in Children.
Keuning MW; Grobben M; de Groen AC; Berman-de Jong EP; Bijlsma MW; Cohen S; Felderhof M; de Groof F; Molanus D; Oeij N; Rijpert M; van Eijk HWM; Koen G; van der Straten K; Oomen M; Visser R; Linty F; Steenhuis M; Vidarsson G; Rispens T; Plötz FB; van Gils MJ; Pajkrt D
Microbiol Spectr; 2021 Oct; 9(2):e0073121. PubMed ID: 34523985
[TBL] [Abstract][Full Text] [Related]
8. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
[TBL] [Abstract][Full Text] [Related]
9. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.
Castro Dopico X; Muschiol S; Christian M; Hanke L; Sheward DJ; Grinberg NF; Rorbach J; Bogdanovic G; Mcinerney GM; Allander T; Wallace C; Murrell B; Albert J; Karlsson Hedestam GB
J Intern Med; 2021 Sep; 290(3):666-676. PubMed ID: 34008203
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.
Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG
J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794
[TBL] [Abstract][Full Text] [Related]
11. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin.
Emmerich P; Murawski C; Ehmen C; von Possel R; Pekarek N; Oestereich L; Duraffour S; Pahlmann M; Struck N; Eibach D; Krumkamp R; Amuasi J; Maiga-Ascofaré O; Rakotozandrindrainy R; Asogun D; Ighodalo Y; Kann S; May J; Tannich E; Deschermeier C
Trop Med Int Health; 2021 Jun; 26(6):621-631. PubMed ID: 33666297
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
[TBL] [Abstract][Full Text] [Related]
13. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.
Fenwick C; Croxatto A; Coste AT; Pojer F; André C; Pellaton C; Farina A; Campos J; Hacker D; Lau K; Bosch BJ; Gonseth Nussle S; Bochud M; D'Acremont V; Trono D; Greub G; Pantaleo G
J Virol; 2021 Jan; 95(3):. PubMed ID: 33144321
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
[TBL] [Abstract][Full Text] [Related]
15. A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays.
Pinto LA; Shawar RM; O'Leary B; Kemp TJ; Cherry J; Thornburg N; Miller CN; Gallagher PS; Stenzel T; Schuck B; Owen SM; Kondratovich M; Satheshkumar PS; Schuh A; Lester S; Cassetti MC; Sharpless NE; Gitterman S; Lowy DR
Microbiol Spectr; 2022 Feb; 10(1):e0156421. PubMed ID: 35019677
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA.
Dileepan M; Di D; Huang Q; Ahmed S; Heinrich D; Ly H; Liang Y
Virulence; 2021 Dec; 12(1):1597-1609. PubMed ID: 34125647
[TBL] [Abstract][Full Text] [Related]
17. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening".
Jin DK; Nesbitt DJ; Yang J; Chen H; Horowitz J; Jones M; Vandergaast R; Carey T; Reiter S; Russell SJ; Kyratsous C; Hooper A; Hamilton J; Ferreira M; Deng S; Straus D; Baras A; Hillyer CD; Luchsinger LL
PLoS One; 2021; 16(4):e0250319. PubMed ID: 33909646
[TBL] [Abstract][Full Text] [Related]
19. Nucleocapsid and Spike Protein-Based Anti-SARS-CoV-2 Assay Performance in the Minority and Rural Coronavirus Insights Study: Characteristics of Socioeconomically Disadvantaged Populations with Health Disparities.
Christenson RH; Hansel S; II'yasova D; Meyer WA; Puckrein G; Lee L; Landry LG; Akinboboye O
J Appl Lab Med; 2024 May; 9(3):493-501. PubMed ID: 38384143
[TBL] [Abstract][Full Text] [Related]
20. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
